FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting DECNUPAZ marks AbbVies first ADC approved for blood cancer NORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks To view or add a comment, sign in We've achieved 82% stable disease per RECIST, with 9 of 11 evaluable patients achieving stable disease, including one patient maintaining stable disease for over 15 months and another for 12 months
Healthcare professionals will consider several factors before recommending this combination, including the patient's complete medication profile, existing medical conditions, treatment goals, and previous responses to either medication
As of the 2026 WADA Prohibited List, semaglutide and other GLP-1 receptor agonists are NOT on the banned substance list
cosmetic claims are out of scope of research-use-only product positioning
Responsible use is essential , which includes supervision by a knowledgeable practitioner
